RGEN
REPLIGEN CORP
$125.33
+2.47%
$7.1B
No data for this timeframe.
Vol
Market Cap$7.1B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders8 funds
Inst. Value$1.6B
Inst. Activity2 buys / 2 sells
Insider Activity0B / 1S
Insider Net $-$536.5K
SEC Reports3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0000730272·Prev Close $122.31
Recent Activity
May 22, 2026
other
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
<p>WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sci
May 14, 2026
Insider
Pax Margaret sold 995 shares
Director @ $0.00 ($0.00)
May 14, 2026
Insider
BARTHELEMY NICOLAS sold 995 shares
Director @ $0.00 ($0.00)
May 14, 2026
Insider
BARTHELEMY NICOLAS sold 2,239 shares
Director @ $0.00 ($0.00)
May 5, 2026
SEC
Repligen reported Q1 2026 adjusted EPS of $0.48, beating the $0.38 consensus by 26.3%, and revenue of $194M (+15% YoY, +
PRESS-RELEASE — Impact 7/10
May 5, 2026
SEC
Repligen reported Q1 2026 revenue of $194M (+15% YoY, +11% organic) and adjusted EPS of $0.48, beating the $0.38 consens
8-K — Impact 7/10
Apr 22, 2026
SEC
Repligen Corporation announced it will report Q1 2026 financial results on May 5, 2026, with no financial data released
PRESS-RELEASE — Impact 3/10
Inst.
NORGES BANK — NEW
462,094 shares ($75.7M)
Price Targets
$176.11
+35.3% upside
Strong Buy
Current $130.13
Low $142.00
Median $180.00
High $220.00
19 analysts
$142.00
$220.00
Analyst Ratings
7Strong Buy
16Buy
5Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | HSBC | MAINTAIN | Buy → Buy |
| May 6, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| May 6, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Apr 20, 2026 | Canaccord Genuity | MAINTAIN | Hold → Hold |
| Apr 17, 2026 | Roth Capital | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.45 ▼ -3.0% | $0.41 — $0.48 | 22% YoY | 17 |
| Next Q | $0.47 ▼ -8.5% | $0.42 — $0.55 | 3% YoY | 17 |
| Current FY | $2.00 ▲ +1.7% | $1.97 — $2.03 | 17% YoY | 21 |
| Next FY | $2.55 ▲ +1.1% | $1.87 — $2.73 | 27% YoY | 20 |
Latest Reports
BULLISH
PRESS-RELEASE
7/10
Repligen reported Q1 2026 adjusted EPS of $0.48, beating the $0.38 consensus by 26.3%, and revenue of $194M (+15% YoY, +
May 5, 2026
BULLISH
8-K
7/10
Repligen reported Q1 2026 revenue of $194M (+15% YoY, +11% organic) and adjusted EPS of $0.48, beating the $0.38 consens
May 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $818.3M | — |
| FMR LLC | $469.9M | ADD |
| MORGAN STANLEY | $93.6M | — |
| NORGES BANK | $75.7M | NEW |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $70.6M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 14, 2026 | Pax Margaret | A | $0.00 |
| May 14, 2026 | BARTHELEMY NICOLAS | A | $0.00 |
| May 14, 2026 | BARTHELEMY NICOLAS | A | $0.00 |
| May 14, 2026 | Konstantinov Konstantin | A | $0.00 |
| May 14, 2026 | Mhatre Rohin | A | $0.00 |
8 institutional holders with $1.6B total value (9,767,664 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4,993,945 | $818.3M | 51.1% | — |
| 2 | FMR LLC | 2,867,846 | $469.9M | 29.4% | ADD +66.8% |
| 3 | MORGAN STANLEY | 570,977 | $93.6M | 5.8% | — |
| 4 | NORGES BANK | 462,094 | $75.7M | 4.7% | NEW |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 430,704 | $70.6M | 4.4% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 397,229 | $65.1M | 4.1% | — |
| 7 | WELLS FARGO & COMPANY/MN | 36,469 | $6.0M | 0.4% | ADD +62.2% |
| 8 | TWO SIGMA INVESTMENTS, LP | 8,400 | $1.4M | 0.1% | NEAR_EXIT -91.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 462,094 | — | $75.7M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 22,479 | 36,469 | +62.2% | $6.0M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 94,861 | 8,400 | -91.1% | $1.4M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 109,404 | 0 | -100.0% | $0.00 | 2025-Q4 |
| FMR LLC | ADD | 1,613,304 | 2,691,212 | +66.8% | $359.7M | 2025-Q3 |
| UBS Group AG | ADD | 295,198 | 456,929 | +54.8% | $61.1M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 66,304 | 109,404 | +65.0% | $14.6M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 313,143 | 94,861 | -69.7% | $12.7M | 2025-Q3 |
| NORGES BANK | EXIT | 249,167 | 0 | -100.0% | $0.00 | 2025-Q3 |
| FMR LLC | DOUBLED | 732,404 | 1,613,304 | +120.3% | $200.7M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 225,306 | 313,143 | +39.0% | $38.9M | 2025-Q2 |
| NORGES BANK | NEW | — | 249,167 | — | $31.0M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 66,304 | — | $8.2M | 2025-Q2 |
| UBS Group AG | ADD | 188,811 | 241,074 | +27.7% | $30.7M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 359,039 | 225,306 | -37.2% | $28.7M | 2025-Q1 |
| NORGES BANK | EXIT | 166,975 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 591,461 | 1,261,502 | +113.3% | $181.6M | 2024-Q4 |
| UBS Group AG | DOUBLED | 93,203 | 188,811 | +102.6% | $27.2M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 7,801 | 19,303 | +147.4% | $2.8M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 363,379 | — | $54.1M | 2024-Q3 |
14 unique insiders with 1 transactions. Net insider value: -$536.5K ($0.00 bought, $536.5K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 14, 2026 | Pax Margaret | Director | A | 995 | $0.00 | $0.00 |
| May 14, 2026 | BARTHELEMY NICOLAS | Director | A | 995 | $0.00 | $0.00 |
| May 14, 2026 | BARTHELEMY NICOLAS | Director | A | 2,239 | $0.00 | $0.00 |
| May 14, 2026 | Konstantinov Konstantin | Director | A | 995 | $0.00 | $0.00 |
| May 14, 2026 | Mhatre Rohin | Director | A | 995 | $0.00 | $0.00 |
| May 14, 2026 | EGLINTON MANNER CARRIE | Director | A | 995 | $0.00 | $0.00 |
| May 14, 2026 | DAWES KAREN A | Director | A | 2,239 | $0.00 | $0.00 |
| May 14, 2026 | Konstantinov Konstantin | Director | A | 2,239 | $0.00 | $0.00 |
| May 14, 2026 | DAWES KAREN A | Director | A | 995 | $0.00 | $0.00 |
| May 14, 2026 | MUIR GLENN P | Director | A | 995 | $0.00 | $0.00 |
| May 14, 2026 | MUIR GLENN P | Director | A | 2,239 | $0.00 | $0.00 |
| May 14, 2026 | Pax Margaret | Director | A | 2,239 | $0.00 | $0.00 |
| May 14, 2026 | Madaus Martin D | Director | A | 995 | $0.00 | $0.00 |
| May 14, 2026 | Madaus Martin D | Director | A | 2,239 | $0.00 | $0.00 |
| May 14, 2026 | EGLINTON MANNER CARRIE | Director | A | 2,239 | $0.00 | $0.00 |
| May 14, 2026 | Mhatre Rohin | Director | A | 2,239 | $0.00 | $0.00 |
| May 7, 2026 | Douglass Brian Robb | CHIEF PRODUCT OFFICER | F | 334 | $126.43 | $42.2K |
| May 7, 2026 | MUIR GLENN P | Director | M | 2,434 | $38.76 | $94.3K |
| May 7, 2026 | MUIR GLENN P | Director | M | 2,434 | $0.00 | $0.00 |
| Apr 21, 2026 | Loeillot Olivier | Chief Executive Officer | SELL | 3,832 | $140.00 | $536.5K |
| Mar 5, 2026 | KURIYEL RALF | Senior VP, R&D | A | 5,284 | $0.00 | $0.00 |
| Mar 5, 2026 | KURIYEL RALF | Senior VP, R&D | A | 5,669 | $0.00 | $0.00 |
| Mar 5, 2026 | Loeillot Olivier | Chief Executive Officer | A | 25,890 | $0.00 | $0.00 |
| Mar 5, 2026 | Garland Jason K | CFO | A | 7,751 | $0.00 | $0.00 |
| Mar 5, 2026 | Garland Jason K | CFO | A | 8,315 | $0.00 | $0.00 |
| Mar 5, 2026 | Bylund James | Chief Operating Officer | A | 7,751 | $0.00 | $0.00 |
| Mar 5, 2026 | Bylund James | Chief Operating Officer | A | 8,315 | $0.00 | $0.00 |
| Mar 5, 2026 | Loeillot Olivier | Chief Executive Officer | A | 24,134 | $0.00 | $0.00 |
| Mar 4, 2026 | Bylund James | Chief Operating Officer | A | 125 | $0.00 | $0.00 |
| Mar 4, 2026 | KURIYEL RALF | Senior VP, R&D | A | 125 | $0.00 | $0.00 |
| Mar 2, 2026 | Bylund James | Chief Operating Officer | F | 2,433 | $124.97 | $304.1K |
| Mar 2, 2026 | Loeillot Olivier | Chief Executive Officer | F | 1,610 | $124.97 | $201.2K |
| Mar 2, 2026 | Hunt Anthony | Director | F | 9,897 | $124.97 | $1.2M |
| Mar 2, 2026 | Garland Jason K | CFO | F | 715 | $124.97 | $89.4K |
| Mar 2, 2026 | KURIYEL RALF | Senior VP, R&D | F | 923 | $124.97 | $115.3K |
| Mar 2, 2026 | Douglass Brian Robb | CHIEF PRODUCT OFFICER | F | 221 | $124.97 | $27.6K |
| Feb 27, 2026 | Garland Jason K | CFO | F | 327 | $128.73 | $42.1K |
| Feb 27, 2026 | Loeillot Olivier | Chief Executive Officer | F | 344 | $128.73 | $44.3K |
| Feb 27, 2026 | KURIYEL RALF | Senior VP, R&D | F | 444 | $128.73 | $57.2K |
| Feb 27, 2026 | Bylund James | Chief Operating Officer | F | 1,478 | $128.73 | $190.3K |
3 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.7/10.
BULLISH
PRESS-RELEASE
7/10
Repligen reported Q1 2026 adjusted EPS of $0.48, beating the $0.38 consensus by 26.3%, and revenue o
May 5, 2026
BULLISH
8-K
7/10
Repligen reported Q1 2026 revenue of $194M (+15% YoY, +11% organic) and adjusted EPS of $0.48, beati
May 5, 2026
NEUTRAL
PRESS-RELEASE
3/10
Repligen Corporation announced it will report Q1 2026 financial results on May 5, 2026, with no fina
Apr 22, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (82% buy). Based on 28 analysts: 7 strong buy, 16 buy, 5 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$176.11 mean target
+35.3% upside
Strong Buy (1.55)
$142.00 Low
$220.00 High
| Metric | Value |
|---|---|
| Current Price | $130.13 |
| Target Low | $142.00 |
| Target Mean | $176.11 |
| Target Median | $180.00 |
| Target High | $220.00 |
| # Analysts | 19 |
| Recommendation | Strong Buy (1.55) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.45 | $0.41 | $0.48 | 22.5% | -3.0% | 2↑ 10↓ | $0.2B | 10.4% | 17 |
| Next Q 2026-09-30 |
$0.47 | $0.42 | $0.55 | 2.9% | -8.5% | 1↑ 14↓ | $0.2B | 9.3% | 17 |
| Current FY 2026-12-31 |
$2.00 | $1.97 | $2.03 | 17.1% | +1.7% | 15↑ 0↓ | $0.8B | 11.5% | 21 |
| Next FY 2027-12-31 |
$2.55 | $1.87 | $2.73 | 27.2% | +1.1% | 10↑ 4↓ | $0.9B | 14.8% | 20 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.453 | |
| 7d ago | $0.453 | |
| 30d ago | $0.467 | -0.014 |
| 60d ago | $0.466 | -0.013 |
| 90d ago | $0.466 | -0.013 |
9 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | HSBC | MAINTAIN | Buy | Buy |
| May 6, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| May 6, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 20, 2026 | Canaccord Genuity | MAINTAIN | Hold | Hold |
| Apr 17, 2026 | Roth Capital | INITIATE | — | Buy |
| Apr 14, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 6, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Mar 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | UBS | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Feb 25, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 25, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Jan 16, 2026 | UBS | MAINTAIN | Buy | Buy |
| Dec 15, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
| Dec 15, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 16 | 5 | 0 | 0 | 82% | |
| May 1, 2026 | 7 | 17 | 5 | 0 | 0 | 83% | |
| Apr 1, 2026 | 7 | 16 | 5 | 0 | 0 | 82% | |
| Mar 1, 2026 | 7 | 16 | 5 | 0 | 0 | 82% | |
| Feb 1, 2026 | 7 | 16 | 5 | 0 | 0 | 82% | |
| Jan 1, 2026 | 7 | 16 | 5 | 0 | 0 | 82% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 22, 2026
other
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
<p>WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology
May 20, 2026
other
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
<p>WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology
May 18, 2026
dark_pool
Dark Pool: RGEN — 2.4M shares, 37,314 trades
Week starting 2026-05-18. Total ATS volume: 2,411,802 shares across 37,314 trades.
May 11, 2026
dark_pool
Dark Pool: RGEN — 3.2M shares, 46,391 trades
Week starting 2026-05-11. Total ATS volume: 3,222,875 shares across 46,391 trades.
May 6, 2026
short_volume
Short Volume: RGEN — 55.2% short (0.3M / 0.5M)
Short: 292,702 | Exempt: 671 | TRF Vol: 529,957 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
May 5, 2026
earnings
Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
<p>WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology
May 5, 2026
earnings_calendar
RGEN Q1 2026 Earnings Before Market Open — 2026-05-05
May 4, 2026
dark_pool
Dark Pool: RGEN — 2.3M shares, 40,806 trades
Week starting 2026-05-04. Total ATS volume: 2,296,183 shares across 40,806 trades.
May 4, 2026
short_interest
FTD: RGEN — 23,794 shares ($2.8M) failed to deliver
Settlement: 20260504, Price: $117.20, FTD Value: $2,788,656.8, REPLIGEN CORP
May 1, 2026
short_interest
FTD: RGEN — 41,956 shares ($5.0M) failed to deliver
Settlement: 20260501, Price: $118.31, FTD Value: $4,963,814.36, REPLIGEN CORP
Apr 27, 2026
dark_pool
Dark Pool: RGEN — 1.7M shares, 33,462 trades
Week starting 2026-04-27. Total ATS volume: 1,731,699 shares across 33,462 trades.
Apr 24, 2026
short_interest
FTD: RGEN — 35,140 shares ($4.0M) failed to deliver
Settlement: 20260424, Price: $114.06, FTD Value: $4,008,068.4, REPLIGEN CORP
Apr 22, 2026
earnings
Repligen to Report First Quarter 2026 Financial Results
Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET <pre>Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00
Apr 21, 2026
short_volume
Short Volume: RGEN — 77.6% short (0.4M / 0.5M)
Short: 415,122 | Exempt: 0 | TRF Vol: 535,268 | Short Ratio: 77.6% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
dark_pool
Dark Pool: RGEN — 2.2M shares, 36,027 trades
Week starting 2026-04-20. Total ATS volume: 2,187,827 shares across 36,027 trades.